TMCnet News
Juneau Biosciences Presents New Genetic Discoveries in Endometriosis at ASRM Scientific Congress & ExpoSALT LAKE CITY, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED) (“Predictive”), reports that Kenneth Ward, M.D., CEO of Juneau Biosciences, LLC, presented new scientific discoveries concerning the genetics of endometriosis at the 74th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo underway in Denver, Colo. Juneau Biosciences is a majority-owned subsidiary of Predictive. Dr. Ward’s paper, entitled “Can Genetic Markers of Endometriosis Predict a Patient’s Responsiveness to Leuprolide Acetate,” addresses the impact genes underlying endometriosis have on the degree of relief a patient receives when prescribed leuprolide acetate, the most widely used FDA-approved therapy for endometriosis. Dr. Ward’s paper was recognized with the ASRM Scientific Program Committee’s “Best in Clinical/Population Science Prize Paper” research award. On October 10 representatives from Juneau will make three additional scientific presentations based on data from Predictive’s Genealogy Database (GenDB™), exploring the use of extended family trees in disease gene discovery. Two of these presentations examine the lineage of families with the largest presence of genes linked to endometriosis reported to date. One family tree spans 19 generations and includes over 250 women living with surgically-confirmed endometriosis, all descendants of a man born in 1608. Data from GenDB suggests that more than 1 million women in the United States may carry this family’s risk factor. “Predictive is using its powerful GenDB™ database to increase the efficiency and thoroughness of gene discoveries in complex diseases,” said Bradley Robinson, CEO of Predictive Technology Group. “As Predictive scales its genomics and artificial intelligence capabilities, our objective is to transform the diagnosis, prediction and treatment of common diseases that lead to tremendous human suffering.” Predictive and Juneau have employed state-of-the-art genomic methods to uncover hundreds of genes that play a role in endoetriosis development and progression. The companies’ population genetics research underlies the novel ARTGuide™ test, a first-of-its-kind non-invasive diagnostic test for endometriosis and other genetic causes of infertility, recently launched by Predictive subsidiary Predictive Diagnostics. ASRM is an international and multi-disciplinary organization devoted to advancing knowledge and expertise in reproductive medicine and biology, with a particular focus on human infertility. About Endometriosis: About Predictive Technology Group, Inc. Forward-Looking Statements Contact: Investors |